IQVIA (NYSE:IQV) Insider Sells 2,668 Shares

IQVIA Holdings Inc. (NYSE:IQV) insider James Berkshire sold 2,668 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total transaction of $697,228.44. Following the sale, the insider owned 10,890 shares in the company, valued at $2,845,883.70. This represents a 19.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

IQVIA Trading Down 1.6%

Shares of NYSE:IQV traded down $4.28 during trading on Friday, reaching $267.34. The company’s stock had a trading volume of 1,197,834 shares, compared to its average volume of 1,736,455. The stock has a market capitalization of $44.00 billion, a PE ratio of 33.17, a price-to-earnings-growth ratio of 2.25 and a beta of 1.18. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $271.80. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The firm’s 50 day simple moving average is $229.01 and its two-hundred day simple moving average is $192.13.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. During the same period in the previous year, the firm posted $2.81 earnings per share. The firm’s revenue for the quarter was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, research analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its Board of Directors has approved a share buyback program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on IQV. Robert W. Baird increased their price target on IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. Stifel Nicolaus boosted their price objective on shares of IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Mizuho raised their target price on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Finally, Wall Street Zen cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, August 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $243.62.

Institutional Investors Weigh In On IQVIA

Several large investors have recently added to or reduced their stakes in IQV. Financial Freedom LLC bought a new position in IQVIA in the 1st quarter worth about $25,000. Ascentis Independent Advisors bought a new stake in shares of IQVIA during the first quarter valued at approximately $25,000. International Assets Investment Management LLC purchased a new stake in shares of IQVIA in the fourth quarter valued at approximately $27,000. Compass Financial Management LLC purchased a new stake in shares of IQVIA in the second quarter valued at approximately $27,000. Finally, Gilpin Wealth Management LLC bought a new position in IQVIA in the fourth quarter worth approximately $27,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.